<DOC>
	<DOCNO>NCT01006226</DOCNO>
	<brief_summary>The purpose study determine : - Whether bevacizumab increase amount oxygen cancer measure special positron emission tomography ( PET ) scan use 64Cu-ATSM . - Whether amount oxygen cancer measure 64Cu-ATSM PET scan predicts well cancer respond treatment chemotherapy .</brief_summary>
	<brief_title>64CuATSM Hypoxia Stage IV Non-small Cell Lung Cancer With Carboplatin , Paclitaxel , Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must histologically cytologically confirm nonsquamous NSCLC . Clinically pathologically proven Stage IV NSCLC . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm irrespective scanner type . No previous chemotherapy . Age &gt; 18 year . Because dose adverse event data currently available use 64CuATSM combination paclitaxel , carboplatin , bevacizumab patient &lt; 18 year age , child exclude study eligible future pediatric phase 2 combination trial . ECOG performance status 01 . Patients must normal organ marrow function define : hemoglobin &gt; 9 gm/dL absolute neutrophil count &gt; 1,500/mcL platelet &gt; 100,000/mcL total bilirubin &lt; 1.5 mg/dL AST ( SGOT ) /ALT ( SGPT ) &lt; 3 X institutional upper limit normal alkaline phosphatase &lt; 3 X institutional upper limit normal creatinine &lt; 1.5 X institutional upper limit normal OR creatinine clearance &gt; 60 mL/min/1.73 m2 ( Cockcroft Gault ) urine dipstick proteinuria &lt; 1+ Adequate coagulation function INR &lt; 1.5 PTT &lt; institutional upper limit normal . The effect 64CuATSM develop human fetus recommend image dose unknown . For reason chemotherapeutic agent well therapeutic agent use trial know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability patient understand willingness sign write informed consent document . Patients prior chemotherapy . Patients prior radiation therapy lung cancer . Patients may receive investigational agent . Patients known central nervous system metastasis . History allergic reaction attribute compound similar chemical biologic composition 64CuATSM agent use study . History claustrophobia , since patient might able tolerate 64CuATSMPET image . History gross hemoptysis bright red blood &gt; Â½ teaspoon quantity past 6 month . Any concurrent history active malignancy prior five year except basal cell skin cancer carcinoma situ cervix . History thrombotic hemorrhagic disorder . Anticoagulation treatment/therapeutic dos . Uncontrolled hypertension . Preexisting neuropathy &gt; grade 1 . Treatment aspirin &gt; 325 mg/day , dipyridamole , ticlopidine , clopidogrel , and/or cilostazol discontinue . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study paclitaxel , carboplatin , bevacizumab agent potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother paclitaxel , carboplatin , bevacizumab , breastfeed discontinue mother treated agent . These potential risk may also apply agent use study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>